Recursion Pharmaceuticals, Inc. (RXRX) Balance Sheet

As of 2026-06-30 (10-Q), Recursion Pharmaceuticals, Inc. (RXRX) reported total assets of $1.2B, total liabilities of $297.7M and shareholders' equity of $915.0M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $545.7M. Long-term debt: $4.8M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

RXRXRecursion Pharmaceuticals, Inc.Follow RXRX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 2.0B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 11 Nov, in 18 days

Line	FY2021 Dec 21	FY2022 Dec 22	FY2023 Dec 23	FY2024 Dec 24	FY2025 Dec 25	Latest Jun 26
Cash and equivalents	0.29	0.55	0.39	0.59	0.74	0.55
Short-term investments	0.23	0.00	—	—	—	—
Receivables	0.00	0.00	—	—	—	—
Current assets	0.53	0.57	0.44	0.71	0.81	0.60
Total assets	0.61	0.70	0.65	1.45	1.47	1.21
Current liabilities	0.05	0.10	0.09	0.19	0.15	0.12
Long-term debt	0.00	0.00	0.00	0.02	0.01	0.00
Short-term debt	—	—	0.00	0.01	0.01	0.01
Total liabilities	0.07	0.22	0.19	0.41	0.34	0.30
Shareholders' equity	0.54	0.49	0.46	1.03	1.13	0.92

USD billions · SEC XBRL

Recursion Pharmaceuticals, Inc. — questions

How much cash does Recursion Pharmaceuticals, Inc. have?: $545.7M in cash and cash equivalents as of 2026-06-30.
How much debt does Recursion Pharmaceuticals, Inc. have?: $4.8M of long-term debt and $9.4M due within a year as of 2026-06-30.
What are Recursion Pharmaceuticals, Inc.'s total assets?: $1.2B as of 2026-06-30.
What is Recursion Pharmaceuticals, Inc.'s shareholders' equity?: $915.0M as of 2026-06-30.

Every figure on this page comes from Recursion Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.